CARDIAC DYSFUNCTIONS CAUSED BY HISTAMINE RELEASE
CARDIAC DYSFUNCTIONS CAUSED BY HISTAMINE RELEASE
批准号:
2685317
负责人:
ROBERTO LEVI
金额:
$41.5万
依托单位国家:
美国
项目类别:
财政年份:
1985
资助国家:
美国
项目状态:
已结题
起止时间:
1985-09-10 至 2001-03-31
关键词:
biological signal transduction bradykinin capsaicin dogs electrophysiology guinea pigs heart disorder heart pharmacology high performance liquid chromatography histamine receptor histamine release human tissue laboratory rat mast cell myocardial ischemia /hypoxia neuropeptide Y neurotransmitter transport nitric oxide norepinephrine potassium channel radioimmunoassay sympathetic nervous system tissue /cell culture
中文摘要
组胺(HA),在心脏肥大细胞中以显著浓度存在
细胞(MC),通过免疫或通过缺血-再灌注(I/R)释放,
引起严重的H2受体(H2 R)介导的快速性心律失常。这些MC在
靠近交感神经末梢(SNT),我们有
最近发现含有不同的HA受体亚型H3 R,
下调去甲肾上腺素(NE)释放。H3 R静止,但完全
激活肾上腺素能状态,如心肌缺血,当HA
被大量释放。我们将测试H3 R也是
在衰竭的心脏中被激活因为心脏MC暴露于
从邻近的SNT释放的神经肽(例如,NPY)和感觉C-
纤维(例如,CGRP),我们将研究NPY和CGRP对
在正常和缺血条件下的心脏HA释放。此外,我们将
直接研究与H3 R相关的转导机制-
介导的正常和缺血SNT中NE释放的抑制
(突触体)从豚鼠心脏分离,从犬心脏中分离
失败和从手术标本的人右心房。飞行员帮助
数据,我们假设H3 R减弱NE胞吐(与急性
缺血)和“载体介导的”释放(与延长的
缺血和Na+/H+逆向转运蛋白激活),通过抑制PI周转,
PKC活性。事实上,我们发现缓激肽(BK),这是已知的,
刺激Na+/H+交换器,增加NE释放,
长期缺血因此,我们建议表征受体
介导BK诱导增强的亚型和转导机制
持续性心肌缺血时NE释放的变化。在其他假定的
心脏交感神经传递的内源性调节剂,我们计划
在心脏突触体中研究一氧化氮(NO)的作用,
我们发现它可以增强或减少NE的胞吐作用,
浓度.我们建议确定调解机制,
NO的促进和抑制作用,重点是NO是否
通过Ca 2+依赖性或非依赖性机制促进NE释放,
NO是否通过激活高电导Kca抑制NE释放
通道,从而使SNT超极化,并减少Ca 2+进入,
胞吐作用感染性休克,重症监护室的主要死亡原因
单位,其特征在于NO过量产生,抑制心肌
收缩性和肾上腺素能紊乱。在感染性休克模型中,我们将
确定主治心力衰竭是否与
NE释放减少,反映了高NO浓度对
SNT。总的来说,拟议的研究将评估保护性
和心脏HA释放的有害作用及其调节,
多种刺激,以及参与H3 R的转导机制
发信号。SNT功能的其他内源性调节剂(BK和DNF)的作用也被证实。
否)将被定义。因此,拟议的研究将产生新的
和重要的信息对新的治疗发展
心血管疾病的治疗策略。
英文摘要
Histamine (HA), present in significant concentrations in cardiac mast
cells (MC), is released immunologically or by ischemia-reperfusion (I/R),
causing severe H2-receptor(H2R)-mediated tachyarrhythmias. These MC are in
close proximity to sympathetic nerve terminals (SNT), which we have
recently discovered to contain a different HA receptor subtype, H3R, that
downregulates norepinephrine (NE) release. H3R quiescent, yet fully
activated in hyperadrenergic states, such as myocardial ischemia, when HA
is copiously released. We will test the hypothesis that H3R are also
activated in the failing heart. Because cardiac MC are exposed to
neuropeptides released from neighboring SNT (e.g., NPY) and sensory C-
fibers (e.g., CGRP), we will investigate the influence of NPY and CGRP on
cardiac HA release in normal and ischemic conditions. Further, we will
directly investigate the transductional mechanisms associated with H3R-
mediated inhibition of NE release in normal and ischemic SNT
(synaptosomes) isolated from guinea pig hearts, from dogs in cardiac
failure and from surgical specimens of human right atrium. Helped by pilot
data, we postulate that H3R attenuate NE exocytosis (associated with acute
ischemia) and "carrier-mediated" release (associated with protracted
ischemia and Na+/H+ antiporter activation), by inhibiting PI turnover and
PKC activity. Indeed, we find that bradykinin (BK), which is known to
stimulate the Na+/H+ exchanger, increases NE release associated with
protracted ischemia. Accordingly, we propose to characterize the receptor
subtype and transductional mechanisms mediating the BK-induced enhancement
of NE release in protracted myocardial ischemia. Among other putative
endogenous modulators of cardiac sympathetic neurotransmission, we plan to
investigate in cardiac synaptosomes the effects of nitric oxide (NO),
which we find to enhance or decrease NE exocytosis as a function of its
concentration. We propose to determine the mechanisms mediating the
facilitatory and inhibitory action of NO, focussing on whether NO
facilitates NE release via a Ca2+-dependent or independent mechanism, and
whether NO inhibits NE release by activating high-conductance Kca
channels, thus hyperpolarizing SNT, and decreasing Ca2+ entry and
exocytosis. Septic shock, the leading cause of death in intensive care
units, is characterized by NO overproduction, depressed myocardial
contractility and adrenergic derangement. In a septic shock model, we will
determine whether the attending cardiac failure is associated with a
decreased NE release reflecting the action of high NO concentrations on
SNT. Collectively, the proposed studies will assess both the protective
and deleterious effects of cardiac HA release and its modulation by
multiple stimuli, as well as the transductional mechanisms involved in H3R
signaling. The role of other endogenous modulators of SNT function (BK and
NO) will be defined. Accordingly, the proposed studies will generate novel
and significant information towards the development of new therapeutic
strategies in cardiovascular diseases.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Histamine Receptor Norepinephrine in Cardiac Dysfunction
-
批准号:8260207
-
项目类别:
-
资助金额:$49.33万
-
财政年份:2010
-
负责人:ROBERTO LEVI
-
依托单位:
Histamine Receptor Norepinephrine in Cardiac Dysfunction
-
批准号:7888932
-
项目类别:
-
资助金额:$50.29万
-
财政年份:2010
-
负责人:ROBERTO LEVI
-
依托单位:
Histamine Receptor Norepinephrine in Cardiac Dysfunction
-
批准号:8458958
-
项目类别:
-
资助金额:$46.59万
-
财政年份:2010
-
负责人:ROBERTO LEVI
-
依托单位:
Histamine Receptor Norepinephrine in Cardiac Dysfunction
-
批准号:8068249
-
项目类别:
-
资助金额:$49.78万
-
财政年份:2010
-
负责人:ROBERTO LEVI
-
依托单位:
Ang II and Norepinephrine in Cardiac Sympathetic Nerves
-
批准号:7012200
-
项目类别:
-
资助金额:$49.22万
-
财政年份:2005
-
负责人:ROBERTO LEVI
-
依托单位:
Ang II and Norepinephrine in Cardiac Sympathetic Nerves
-
批准号:7078069
-
项目类别:
-
资助金额:$5.6万
-
财政年份:2005
-
负责人:ROBERTO LEVI
-
依托单位:
Ang II and Norepinephrine in Cardiac Sympathetic Nerves
-
批准号:7567590
-
项目类别:
-
资助金额:$39.82万
-
财政年份:2005
-
负责人:ROBERTO LEVI
-
依托单位:
Ang II and Norepinephrine in Cardiac Sympathetic Nerves
-
批准号:6869687
-
项目类别:
-
资助金额:$42.0万
-
财政年份:2005
-
负责人:ROBERTO LEVI
-
依托单位:
Ang II and Norepinephrine in Cardiac Sympathetic Nerves
-
批准号:7383071
-
项目类别:
-
资助金额:$47.79万
-
财政年份:2005
-
负责人:ROBERTO LEVI
-
依托单位:
Ang II and Norepinephrine in Cardiac Sympathetic Nerves
-
批准号:7177556
-
项目类别:
-
资助金额:$47.79万
-
财政年份:2005
-
负责人:ROBERTO LEVI
-
依托单位:
PHARMACOLOGY/BIOCHEMISTRY/PATHOPHYSIOLOGY--LEUKOTRIENES
-
批准号:3433481
-
项目类别:
-
资助金额:$0.8万
-
财政年份:1987
-
负责人:ROBERTO LEVI
-
依托单位:
CARDIAC DYSFUNCTIONS CAUSED BY HISTAMINE RELEASE
-
批准号:6183640
-
项目类别:
-
资助金额:$43.81万
-
财政年份:1985
-
负责人:ROBERTO LEVI
-
依托单位:
CARDIAC DYSFUNCTIONS CAUSED BY HISTAMINE RELEASE
-
批准号:2217488
-
项目类别:
-
资助金额:$45.02万
-
财政年份:1985
-
负责人:ROBERTO LEVI
-
依托单位:
CARDIAC DYSFUNCTIONS CAUSED BY HISTAMINE RELEASE
-
批准号:3346959
-
项目类别:
-
资助金额:$34.78万
-
财政年份:1985
-
负责人:ROBERTO LEVI
-
依托单位:
CARDIAC DYSFUNCTIONS CAUSED BY HISTAMINE RELEASE
-
批准号:3346955
-
项目类别:
-
资助金额:$23.13万
-
财政年份:1985
-
负责人:ROBERTO LEVI
-
依托单位:
Histamine Receptor/Norepinephrine in Cardiac Dysfunction
-
批准号:6970417
-
项目类别:
-
资助金额:$54.8万
-
财政年份:1985
-
负责人:ROBERTO LEVI
-
依托单位:
CARDIAC DYSFUNCTIONS CAUSED BY HISTAMINE RELEASE
-
批准号:3346956
-
项目类别:
-
资助金额:$25.65万
-
财政年份:1985
-
负责人:ROBERTO LEVI
-
依托单位:
CARDIAC DYSFUNCTIONS CAUSED BY HISTAMINE RELEASE
-
批准号:2217490
-
项目类别:
-
资助金额:$39.31万
-
财政年份:1985
-
负责人:ROBERTO LEVI
-
依托单位:
Histamine Receptor/Norepinephrine in Cardiac Dysfunction
-
批准号:6536860
-
项目类别:
-
资助金额:$47.39万
-
财政年份:1985
-
负责人:ROBERTO LEVI
-
依托单位:
Histamine Receptor/Norepinephrine in Cardiac Dysfunction
-
批准号:6761737
-
项目类别:
-
资助金额:$55.54万
-
财政年份:1985
-
负责人:ROBERTO LEVI
-
依托单位:
海外基金